Lapsed Jun 3, 2026 on the fee record · High confidence
20-year base term ends May 12, 2028
Third maintenance fee unpaid; grace period ended.
Held by Vyripharm Enterprises, Inc.
Filed Dec 9, 2011 as application 13/316,321 · Granted Jun 3, 2014
Base term, 20 years from filing
Today
Lapsed Jun 3, 2026
2008
2028
Clock starts
May 12, 2008
May 12, 2008
No longer in force
Jun 3, 2026
Jun 3, 2026
Granted
Jun 3, 2014
Jun 3, 2014
Term would have run to
May 12, 2028
May 12, 2028
base term
after the term ends
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 7,943,591, US 8,093,225, to May 12, 2028. The term already ends on or before that date, so the cap shortened nothing.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
5
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
Its term would have run to May 12, 2028: its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts May 12, 2008, when application 12/119,435, the earliest non-provisional in its chain, was filed (this one was filed Dec 9, 2011) | May 12, 2028 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,943,591, US 8,093,225) | resolves to May 12, 2028, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | lapsed Jun 3, 2026 | High confidence |
| Computed term end | The steps above, in order | Jun 3, 2026 | High confidence |
This family
| US 7,943,591 | Lapsed on the fee record May 2023 | May 2023 |
| US 8,093,225 | Lapsed on the fee record Jan 2024 | Jan 2024 |
| US 8,741,864 | this patent Jun 2026 | Jun 2026 |
| US 9,290,762 | Lapsed on the fee record Mar 2024 | Mar 2024 |
| US 10,041,069 | In force May 2028 | May 2028 |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| May 25, 2012 Reel 28273, frame 690 | Mamet, Julien | Adynxx, Inc. | Assignment of Assignor's Interest |
| Jul 3, 2019 Reel 49660, frame 848 | Adynxx, Inc. | Adynxx Sub, Inc. | Change of Name |
| Jul 11, 2019 Reel 49729, frame 101 | Adynxx Sub, Inc. | Oxford Finance LLC, as Collateral Agent | Security Interest |
| Feb 20, 2020 Reel 51980, frame 421 | Adynxx, Inc.; Adynxx Sub, Inc. | Oxford Finance LLC | First Amendment to Intellectual Property Security Agreement |
| Jul 19, 2022 reel/frame not recorded | Oxford Finance LLC, as Collateral Agent | Adynxx Sub, Inc. | Release of Security Interest |
| Jul 19, 2022 reel/frame not recorded | Oxford Finance LLC, as Collateral Agent | Adynxx, Inc. | Release of Security Interest |
| Jul 19, 2022 Reel 60730, frame 583 | Oxford Finance LLC, as the Lawful Attorney-in-Fact of Adynxx Sub, Inc. and Adynxx, Inc. | Vyripharm Enterprises, Inc. | Assignment of Assignor's Interest |
| Jul 19, 2022 Reel 60547, frame 449 | Oxford Finance LLC, as Collateral Agent | Adynxx Sub, Inc.; Adynxx, Inc. | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 7,943,591, US 8,093,225, ends no earlier than this term, so it caps nothing.
Citations
10
later US patents cite this one
That is above the median of utility patents granted in 2014 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.